Soleno Therapeutics Reports Strong Q1 Profitability Amidst Pending Acquisition by Neurocrine Biosciences

summarizeSummary

Soleno Therapeutics reported a significant turnaround to profitability in Q1 2026 with strong revenue growth, while formally confirming the pending acquisition by Neurocrine Biosciences for $53.00 per share.

check_boxKey Events

• Achieved Q1 2026 Profitability

  The company reported net product revenue of $94.6 million and diluted earnings per share of $0.59 for Q1 2026, a significant improvement from a net loss of $43.8 million and diluted EPS of $(0.95) in Q1 2025.

• Pending Acquisition Confirmed

  The filing formally confirms the definitive merger agreement with Neurocrine Biosciences, Inc., where Neurocrine will acquire all outstanding shares for $53.00 per share in cash. The tender offer commenced on April 20, 2026, and is expected to close in Q2 2026.

• EU Marketing Application Withdrawn

  Soleno Therapeutics voluntarily withdrew its Marketing Authorization Application for VIOKAT (VYKAT XR) in the European Union on April 7, 2026, delaying potential commercialization in the region.

• Commercial Milestone Achieved

  The company achieved the second and final commercial milestone of $200 million in cumulative revenue for VYKAT XR during Q1 2026, triggering a $13.8 million contingent payment to former Essentialis stockholders.

auto_awesomeAnalysis

Soleno Therapeutics' Q1 2026 results demonstrate a significant financial turnaround, reporting net product revenue of $94.6 million and diluted earnings per share of $0.59, a substantial improvement from a net loss in the prior year. This strong performance is overshadowed by the formal confirmation of the definitive merger agreement with Neurocrine Biosciences, Inc., where Soleno shareholders are offered $53.00 per share in cash. While the merger news was previously announced, this 10-Q provides the official financial details and context. The company also achieved its second and final commercial milestone for VYKAT XR, triggering a $13.8 million contingent payment. The voluntary withdrawal of the EU marketing application for VYKAT XR is a negative development for international expansion, but its impact is largely mitigated by the pending acquisition, which offers a clear exit strategy for shareholders.